GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » 3-Year RORE %

ARAY (Accuray) 3-Year RORE % : 17.82% (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Accuray 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Accuray's 3-Year RORE % for the quarter that ended in Sep. 2024 was 17.82%.

The industry rank for Accuray's 3-Year RORE % or its related term are showing as below:

ARAY's 3-Year RORE % is ranked better than
74.75% of 804 companies
in the Medical Devices & Instruments industry
Industry Median: -8.355 vs ARAY: 17.82

Accuray 3-Year RORE % Historical Data

The historical data trend for Accuray's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray 3-Year RORE % Chart

Accuray Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.45 -52.17 89.80 13.16 32.08

Accuray Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 4.37 17.52 32.08 17.82

Competitive Comparison of Accuray's 3-Year RORE %

For the Medical Devices subindustry, Accuray's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accuray's 3-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Accuray's 3-Year RORE % falls into.



Accuray 3-Year RORE % Calculation

Accuray's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.17--0.108 )/( -0.348-0 )
=-0.062/-0.348
=17.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Accuray  (NAS:ARAY) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Accuray 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Accuray's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accuray Business Description

Traded in Other Exchanges
Address
1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Executives
Ali Pervaiz officer: SVP Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joseph E Whitters director
Michael Hoge officer: Senior VP Global Operations 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Gina Corradetti officer: VP, Corporate Controller 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew officer: SVP and General Counsel 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke officer: SVP, Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter officer: SVP & Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine officer: SVP, Chief Admin Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill director VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green officer: Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba officer: VP, Chief Accounting Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine officer: President & CEO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Shigeyuki Hamamatsu officer: VP, Finance and CAO 1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043